公司概覽
業務類別 --
業務概覽 Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
公司地址 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
電話號碼 +61 396396036
傳真號碼 +61 396396030
公司網頁 https://www.mesoblast.com
員工數量 81
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Eric A. Rose, M.D. Director and Chief Medical Officer 澳元 701.84K 29/08/2025
Mr. Paul Hughes, B.Bus Joint Company Secretary -- 29/08/2025
Dr. Fiona See, PhD Senior Vice President and Head of Translational Research -- 29/08/2025
Mr. Peter Howard, B.Sc. ,L.L.B. Group General Counsel -- 29/08/2025
Ms. Niva Sivakumar, B.Com,L.L.B. Joint Company Secretary -- 29/08/2025
Dr. Silviu Itescu, F.A.C.P.,F.R.A.C.P. Director and Chief Executive Officer 澳元 757.50K 29/08/2025
Mr. Michael Schuster, M.B.A. Pharma Partnering -- 29/08/2025
Dr. Paul Simmons, PhD Scientific Advisor to the Chief Executive Officer -- 29/08/2025
Ms. Geraldine Storton, B.Sc. ,M.B.A. Head of Regulatory Affairs and Quality Management -- 29/08/2025
Mr. Andrew Chaponnel, B.Com Interim Chief Financial Officer -- 29/08/2025
Mr. Justin Horst, B.S. Head of Manufacturing -- 29/08/2025
 
董事會成員
董事會 職務 更新日期
Dr. Eric A. Rose, M.D. Director and Chief Medical Officer 29/08/2025
Mr. Joseph R. Swedish, M.H.A Independent Director 29/08/2025
Mr. Philip Krause, M.D. Director 29/08/2025
Mr. William J. Burns, B.A. Vice Chairman of the Board 29/08/2025
Mr. Philip J. Facchina Independent Director 29/08/2025
Dr. Silviu Itescu, F.A.C.P.,F.R.A.C.P. Director and Chief Executive Officer 29/08/2025
Ms. Jane Bell, L.L.B.,L.L.M. Chairman of the Board 29/08/2025
Dr. Gregory George, M.D. Director 29/08/2025
Ms. Lyn Cobley, BEc Independent Director 29/08/2025
 
所屬ETF (更新日期: 07/03/2026 02:00)
代號 名稱 佔比% 持有日期
SCHCSchwab International Small-Cap Eq ETF™0.15%28/02/2026
DFISDimensional International Small Cap ETF0.10%27/02/2026
SPDWState Street® SPDR® Ptf Dev Wld exUS ETF0.09%27/02/2026
VTVanguard Total World Stock ETF0.05%31/01/2026
DFICDimensional International Core Eq 2 ETF0.05%27/02/2026
DFAIDimensional International Cr Eq Mkt ETF0.03%27/02/2026
DFAXDimensional World ex US Core Eq 2 ETF0.02%27/02/2026
IPACiShares Core MSCI Pacific ETF0.02%28/02/2026
VSGXVanguard ESG International Stock ETF0.01%31/01/2026
GINNGoldman Sachs Innovate Equity ETF0.01%27/02/2026
WSMLiShares MSCI World Small-Cap ETF0.01%28/02/2026
AVDSAvantis International Small Cp Eq ETF0.01%28/02/2026
DFSIDimensional International Sstby Cr 1 ETF0.003%27/02/2026
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF0.002%27/02/2026
TLTDFlexShares Mstar DevMks exUS FctTilt ETF0.002%27/02/2026
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%27/02/2026
DXIVDimensional International Vector Eq ETF<0.000001%15/12/2025
GWXState Street® SPDR® S&P® Intl Sm Cp ETF<0.000001%22/09/2025
HSCZiShares Currency Hdgd MSCI EAFE SmCp ETF<0.000001%27/02/2026
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.